Safety and Efficacy of Talampanel in Glioblastoma Multiforme
- Study Title
- Safety and Efficacy of Talampanel in Glioblastoma Multiforme
- Teva Identifier
- IXR-207-21-189 / NABTT 0304
- ClinicalTrials.gov Identifier
- NCT00267592
- Study Status
- Completed
- Trial Condition(s)
- Glioblastoma Multiforme
- Interventions
- Drug: Talampanel | Radiation: Radiation Therapy (RT) 5 days a week + | Drug: temozolomide(TMZ) 75mg | Drug: adjuvant TMZ 200mg
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- 12/01/2005 - 02/01/2011
- Phase
- Phase 2
